Savara Inc. (YB4P.F)
| Previous close | 4.1000 |
| Open | 4.1400 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 4.1000 - 4.1400 |
| 52-week range | 1.6600 - 5.0500 |
| Volume | |
| Avg. volume | 33 |
| Market cap | 574.59M |
| Beta (5Y monthly) | 0.70 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3100 |
| Earnings date | 13 May 2024 - 17 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.00 |
Business WireSavara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
LANGHORNE, Pa., April 08, 2024--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of two abstracts for poster presentation at the American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024, in San Diego, CA.
Business WireSavara Announces New Employment Inducement Grant
AUSTIN, Texas, March 22, 2024--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees.
Business WireSavara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update
LANGHORNE, Pa., March 07, 2024--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and full year ending December 31, 2023 and provided a business update.
